Ecolab (ECL)
(Delayed Data from NYSE)
$247.23 USD
+1.00 (0.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $247.10 -0.13 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$247.23 USD
+1.00 (0.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $247.10 -0.13 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Ecolab (ECL) Launches Roach Control Device for Food Outlets
by Zacks Equity Research
Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.
MTX or ECL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MTX vs. ECL: Which Stock Is the Better Value Option?
AXTA vs. ECL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AXTA vs. ECL: Which Stock Is the Better Value Option?
Ecolab (ECL) Misses Q1 Earnings Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of -1.22% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect strength in the Global Healthcare and Life Sciences segment.
Materials Sector to Rejoice in Q1 Earnings: ETFs to Play
by Sweta Killa
The solid trend for materials ETFs is likely to continue as Q1 earnings unfold.
ICL vs. ECL: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. ECL: Which Stock Is the Better Value Option?
4 Chemical Specialty Stocks to Buy From a Rebounding Industry
by Anindya Barman
The Zacks Chemicals Specialty industry is poised to run higher on a rebound in global industrial and manufacturing activities. Celanese (CE), Ashland (ASH), Daqo New Energy (DQ) and Element Solutions (ESI) are set to gain from demand recovery and self-help actions.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
ICL vs. ECL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICL vs. ECL: Which Stock Is the Better Value Option?
Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator
by Zacks Equity Research
Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.
Why Is Ecolab (ECL) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Ecolab (ECL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.
Earnings Preview: Ecolab (ECL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Ecolab (ECL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed a recovery in rapid immunoassay revenues during Q4.
DuPont (DD) Warms Up to Q4 Earnings: What's in the Offing?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from its cost and productivity actions in the fourth quarter.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in Pharmaceutical segment.
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
Air Products (APD) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Benefits of productivity and pricing actions, new plants and acquisitions are expected to get reflected on Air Products' (APD) Q1 results.
CE vs. ECL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CE vs. ECL: Which Stock Is the Better Value Option?
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.